Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy
Uhod Uluslararasi Hematoloji Onkoloji Dergisi · Ocak 2022
YÖKSİS Kayıtları
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI · 2022 EBSCO, İndex Copernicus
PROFESÖR ALİ ÜNLÜ →
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI · 2022 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer Who Underwent Definitive Chemo-Radiotherapy
UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi · 2022 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Prognostic Significance of Serum Human Epididymis Protein 4 Level in Patients with Locally Advanced Non-Small Cell Lung Cancer who Underwent Definitive Chemo-Radiotherapy
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI · 2022 SCI-Expanded
DOKTOR ÖĞRETİM ÜYESİ MÜRSEL DÜZOVA →
Makale Bilgileri
DergiUhod Uluslararasi Hematoloji Onkoloji Dergisi
Yayın TarihiOcak 2022
Cilt / Sayfa32 · 126-132
Scopus ID2-s2.0-85131457344
Erişim🔓 Açık Erişim
Özet
We aimed to investigate the prognostic significance of serum human epididymis protein 4 (HE4) level in patients with locally advanced non-small cell lung cancer (LA-NSCLC) who underwent definitive chemo-radiotherapy (CRT). A hundred seventeen patients with the diagnosis of LA-NSCLC were enrolled. The serum concentrations of HE4 were measured at the beginning of CRT, at the end of CRT, and 3 months after the completion of CRT. The median follow-up period was 21.7 months (range, 5.4-39.8 months). The mean serum HE4 levels prior to CRT, at the end of the CRT, and 3rd month after the completion of CRT were 159.2, 130.2, and 127.5, respectively (p= 0.023). The median progression free survival (PFS) was 15.4 months. One, and two-year PFS rates were 58.1%, and 22.2%, respectively. One, and two-year expected survival rates were 81.2%, and 62%, respectively. In multivariate analysis, stage (p= 0.002), HE4 levels after 3 months of CRT (p= 0.037) were predictive of OS. Stage IIIC patients had 10.2 times likely to death when compared to stage IIIA patients (95%CI: 2.3-45.7; p= 0.037). The increase of 1 HE4 levels after 3 months of CRT increased the mortality rate 1.002 (95%CI: 1.000-1.0004; p= 0.037). In multivariate analysis stage was predictive of PFS. When compared to stage IIIA patients, stage IIIC patients have 2.5 times risk for progression (95% CI: 1.2-5.2; p= 0.014). Our findings suggested that serum HE4 may be an important prognostic biomarker for LA-NSCLC patients. This issue warrants further prospective studies with more patient populations.
Yazarlar (6)
1
Güler Yavaş
2
Sumerya Duru Birgi
ORCID: 0000-0003-4260-1018
3
Ali Ünlü
ORCID: 0000-0002-9991-3939
4
Çaǧdaş Yavaş
5
Mursel Duzova
6
Serap Akyurek
ORCID: 0000-0001-8840-0233
Anahtar Kelimeler
Human epididymis protein 4
Locally advanced
Non-small cell lung cancer
oncurrent chemo-radiotherapy
Kurumlar
Ankara Üniversitesi
Ankara Turkey
Başkent Üniversitesi
Ankara Turkey
Selçuk Tip Fakültesi
Konya Turkey